C4 Therapeutics, Inc. (CCCC)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry.
Company overview
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that degrade disease-related proteins. Its lead candidate, CFT7455, targets multiple myeloma and non-Hodgkin lymphomas. The company also has other drug candidates targeting various cancers and has partnerships with major pharmaceutical firms.
Fundamental
weakC4 Therapeutics faces substantial losses and cash burn, with valuation metrics not applicable due to its development-stage status.
C4 Therapeutics is a development-stage biotech: collaboration revenue is modest while losses and cash burn are large (TTM free cash flow about -$96M; net margin about -298%). SEC filings show a meaningful liquidity buffer (~$268M cash + marketable securities as of 2026-03-31) and no explicit going-concern warning, but the equity is still largely clinical-milestone and financing driven with high volatility.
Sentiment
fairSentiment is modestly positive, buoyed by Russell 2000 inclusion, though lacking near-term catalysts.
Near-term media tone is modestly bullish on Russell 2000 inclusion (technical, announced) and appears improved versus the prior 30–90d window that was mixed on Q1-loss/revenue-miss coverage. With no clearly dated forward catalyst found for the next month and retail/Reddit signal indeterminate (ticker collision + 429), conviction stays mid-range; no active legal/regulatory investigation surfaced in this scan.
Technical
goodThe stock shows a strong bullish trend, but technical indicators suggest it may be overextended.
CCCC has a strong short-term bullish chart: price is above every major daily average and VWAP, MACD is positive and rising, ADX is strong, and liquidity clears the floor; however, RSI/Williams are overbought and recent volume includes a large churn day, so the chart is strong but extended.
You’re looking at 2026-06-30 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.